QuidelOrtho Corporation (QDEL)
The Schall Law Firm Urges Investors Who Have Experienced Losses In QuidelOrtho Corporation To Get In Touch
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.
The Schall Law Firm Encourages Investors Who Have Suffered Losses in QuidelOrtho Corporation to Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.
Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report?
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?
The Schall Law Firm Encourages Investors Who Have Suffered Losses In QuidelOrtho Corporation To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.
The Schall Law Firm Urges Investors With Losses In QuidelOrtho Corporation To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.
QuidelOrtho (QDEL) Investors Who Suffered Substantial Losses After QDEL Reported Disastrous Q4 2023 Results, Terminated CEO, & Withdrew FDA Submission Should Contact Hagens Berman Before June 11, 2024 Deadline
SAN FRANCISCO, CA / ACCESSWIRE / June 5, 2024 / Hagens Berman urges QuidelOrtho Corporation (NASDAQ:QDEL) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 18, 2022 - Apr. 1, 2024 Lead Plaintiff Deadline: June 11, 2024 Visit: www.hbsslaw.com/investor-fraud/QDEL Contact the Firm Now: [email protected] 844-916-0895 QuidelOrtho Corporation (NASDAQ: QDEL) Securities Class Action: The litigation is focused on the propriety of QuidelOrtho's past assurances about its preparedness to maintain a stable high margin revenue stream from its respiratory business in the face of the COVID-19 pandemic becoming an endemic and about its FDA submission for its purported "next flagship product" (the "Savanna RVP4 Test") being "on track.
QDEL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.
QuidelOrtho (QDEL) Investors Who Suffered Substantial Losses After QDEL Reported Disastrous Q4 2023 Results, Terminated CEO, & Withdrew FDA Submission Should Contact Hagens Berman Before June 11, 2024 Deadline
SAN FRANCISCO, CA / ACCESSWIRE / June 3, 2024 / Hagens Berman urges QuidelOrtho Corporation (NASDAQ:QDEL) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 18, 2022 - Apr. 1, 2024 Lead Plaintiff Deadline: June 11, 2024 Visit: www.hbsslaw.com/investor-fraud/QDEL Contact the Firm Now: [email protected] 844-916-0895 QuidelOrtho Corporation (NASDAQ: QDEL) Securities Class Action: The litigation is focused on the propriety of QuidelOrtho's past assurances about its preparedness to maintain a stable high margin revenue stream from its respiratory business in the face of the COVID-19 pandemic becoming an endemic and about its FDA submission for its purported "next flagship product" (the "Savanna RVP4 Test") being "on track.
QDEL CRUCIAL INVESTOR ALERT: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.
Contact Hagens Berman by June 11, 2024 Deadline to Join Class Action Against QuidelOrtho (QDEL)
SAN FRANCISCO, CA / ACCESSWIRE / June 2, 2024 / Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 18, 2022 - Apr. 1, 2024 Lead Plaintiff Deadline: June 11, 2024 Visit: www.hbsslaw.com/investor-fraud/QDEL Contact the Firm Now: [email protected] 844-916-0895 QuidelOrtho Corporation (NASDAQ: QDEL) Securities Class Action: The litigation is focused on the propriety of QuidelOrtho's past assurances about its preparedness to maintain a stable high margin revenue stream from its respiratory business in the face of the COVID-19 pandemic becoming an endemic and about its FDA submission for its purported "next flagship product" (the "Savanna RVP4 Test") being "on track.
CRUCIAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against QuidelOrtho Corporation - QDEL
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ:QDEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
